|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0016360,
umls-concept:C0023413,
umls-concept:C0026882,
umls-concept:C0027651,
umls-concept:C0036525,
umls-concept:C0038952,
umls-concept:C0123931,
umls-concept:C0449438,
umls-concept:C0812241,
umls-concept:C0936012,
umls-concept:C0995188,
umls-concept:C1522484,
umls-concept:C1527249,
umls-concept:C1537502,
umls-concept:C1708063
|
|
pubmed:issue |
15
|
|
pubmed:dateCreated |
2011-5-19
|
|
pubmed:abstractText |
The addition of cetuximab to irinotecan, fluorouracil, and leucovorin (FOLFIRI) as first-line treatment for metastatic colorectal cancer (mCRC) was shown to reduce the risk of disease progression and increase the chance of response in patients with KRAS wild-type disease. An updated survival analysis, including additional patients analyzed for tumor mutation status, was undertaken.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/BRAF protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Camptothecin,
http://linkedlifedata.com/resource/pubmed/chemical/Fluorouracil,
http://linkedlifedata.com/resource/pubmed/chemical/KRAS protein, human,
http://linkedlifedata.com/resource/pubmed/chemical/Leucovorin,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins,
http://linkedlifedata.com/resource/pubmed/chemical/Proto-Oncogene Proteins B-raf,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Epidermal Growth Factor,
http://linkedlifedata.com/resource/pubmed/chemical/cetuximab,
http://linkedlifedata.com/resource/pubmed/chemical/ras Proteins
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
May
|
|
pubmed:issn |
1527-7755
|
|
pubmed:author |
pubmed-author:CascinuStefanoS,
pubmed-author:CelikIlhanI,
pubmed-author:CiardielloFortunatoF,
pubmed-author:CunninghamDavidD,
pubmed-author:FolprechtGunnarG,
pubmed-author:KöhneClaus-HenningCH,
pubmed-author:LángIstvánI,
pubmed-author:MaurelJoanJ,
pubmed-author:NowackiMarek PMP,
pubmed-author:RougierPhilippeP,
pubmed-author:SchlichtingMichaelM,
pubmed-author:ShchepotinIgorI,
pubmed-author:TejparSabineS,
pubmed-author:Van CutsemEricE,
pubmed-author:ZubelAngelaA
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
20
|
|
pubmed:volume |
29
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2011-9
|
|
pubmed:meshHeading |
pubmed-meshheading:21502544-Adult,
pubmed-meshheading:21502544-Aged,
pubmed-meshheading:21502544-Aged, 80 and over,
pubmed-meshheading:21502544-Antibodies, Monoclonal,
pubmed-meshheading:21502544-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:21502544-Camptothecin,
pubmed-meshheading:21502544-Colorectal Neoplasms,
pubmed-meshheading:21502544-Female,
pubmed-meshheading:21502544-Fluorouracil,
pubmed-meshheading:21502544-Humans,
pubmed-meshheading:21502544-Leucovorin,
pubmed-meshheading:21502544-Male,
pubmed-meshheading:21502544-Middle Aged,
pubmed-meshheading:21502544-Mutation,
pubmed-meshheading:21502544-Neoplasm Metastasis,
pubmed-meshheading:21502544-Prognosis,
pubmed-meshheading:21502544-Proto-Oncogene Proteins,
pubmed-meshheading:21502544-Proto-Oncogene Proteins B-raf,
pubmed-meshheading:21502544-Receptor, Epidermal Growth Factor,
pubmed-meshheading:21502544-ras Proteins
|
|
pubmed:year |
2011
|
|
pubmed:articleTitle |
Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status.
|
|
pubmed:affiliation |
University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium. eric.vancutsem@uz.kuleuven.ac.be
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study,
Clinical Trial, Phase III
|
